First Time Loading...

Amneal Pharmaceuticals Inc
NYSE:AMRX

Watchlist Manager
Amneal Pharmaceuticals Inc Logo
Amneal Pharmaceuticals Inc
NYSE:AMRX
Watchlist
Price: 5.7299 USD 6.11%
Updated: Apr 24, 2024

Profitability Summary

We take all the information about a company's profitability (such as its margins, capital efficiency, free cash flow generating ability, and more) and consolidate it into one single number - the profitability score. The higher the profitability score, the more profitable the company is.

Past Growth

To be successful and remain in business, both growth and profitability are important and necessary. Net Income growth is often seen as a sign of a company's efficiency from an operational standpoint, but is influenced heavily by a company's goals and challenges and should therefore be assessed in conjunction with other metrics like revenue and operating income growth.

Margins

Profit margins represent what percentage of sales has turned into profits. Simply put, the percentage figure indicates how many cents of profit the company has generated for each dollar of sale.

Profit margins help investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Earnings Waterfall
Amneal Pharmaceuticals Inc

Revenue
2.4B USD
Cost of Revenue
-1.5B USD
Gross Profit
856.7m USD
Operating Expenses
-581.8m USD
Operating Income
274.8m USD
Other Expenses
-358.8m USD
Net Income
-84m USD

Margins Comparison
Amneal Pharmaceuticals Inc Competitors

Country Company Market Cap Gross
Margin
Operating
Margin
Net
Margin
US
Amneal Pharmaceuticals Inc
NYSE:AMRX
1.8B USD
36%
11%
-4%
JP
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
776 550.9T JPY
-3%
-83%
-79%
US
Eli Lilly and Co
NYSE:LLY
707.9B USD
79%
30%
15%
DK
Novo Nordisk A/S
CSE:NOVO B
3.9T DKK
85%
45%
36%
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP
56%
3%
-4%
JP
Taisho Pharmaceutical Holdings Co Ltd
TSE:4581
82T JPY
57%
6%
3%
US
Johnson & Johnson
NYSE:JNJ
360B USD
70%
29%
50%
US
Merck & Co Inc
NYSE:MRK
321.2B USD
74%
7%
1%
UK
AstraZeneca PLC
LSE:AZN
176.3B GBP
82%
19%
13%
CH
Roche Holding AG
SIX:ROG
177.3B CHF
74%
33%
20%
CH
Novartis AG
SIX:NOVN
184.3B CHF
74%
27%
32%
Country US
Market Cap 1.8B USD
Gross Margin
36%
Operating Margin
11%
Net Margin
-4%
Country JP
Market Cap 776 550.9T JPY
Gross Margin
-3%
Operating Margin
-83%
Net Margin
-79%
Country US
Market Cap 707.9B USD
Gross Margin
79%
Operating Margin
30%
Net Margin
15%
Country DK
Market Cap 3.9T DKK
Gross Margin
85%
Operating Margin
45%
Net Margin
36%
Country UK
Market Cap 440.4B GBP
Gross Margin
56%
Operating Margin
3%
Net Margin
-4%
Country JP
Market Cap 82T JPY
Gross Margin
57%
Operating Margin
6%
Net Margin
3%
Country US
Market Cap 360B USD
Gross Margin
70%
Operating Margin
29%
Net Margin
50%
Country US
Market Cap 321.2B USD
Gross Margin
74%
Operating Margin
7%
Net Margin
1%
Country UK
Market Cap 176.3B GBP
Gross Margin
82%
Operating Margin
19%
Net Margin
13%
Country CH
Market Cap 177.3B CHF
Gross Margin
74%
Operating Margin
33%
Net Margin
20%
Country CH
Market Cap 184.3B CHF
Gross Margin
74%
Operating Margin
27%
Net Margin
32%

Return on Capital

Return on capital ratios give a sense of how well a company is using its capital (equity, assets, capital employed, etc.) to generate profits (operating income, net income, etc.). In simple words, these ratios show how much income is generated for each dollar of capital invested.

Return on Capital Comparison
Amneal Pharmaceuticals Inc Competitors

Country Company Market Cap ROE ROA ROCE ROIC
US
Amneal Pharmaceuticals Inc
NYSE:AMRX
1.8B USD
-53%
-2%
10%
10%
JP
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
776 550.9T JPY
-441%
-47%
-108%
-64%
US
Eli Lilly and Co
NYSE:LLY
707.9B USD
49%
9%
30%
16%
DK
Novo Nordisk A/S
CSE:NOVO B
3.9T DKK
88%
30%
79%
36%
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP
-4%
-2%
2%
2%
JP
Taisho Pharmaceutical Holdings Co Ltd
TSE:4581
82T JPY
1%
1%
2%
2%
US
Johnson & Johnson
NYSE:JNJ
360B USD
56%
23%
18%
14%
US
Merck & Co Inc
NYSE:MRK
321.2B USD
1%
0%
5%
1%
UK
AstraZeneca PLC
LSE:AZN
176.3B GBP
16%
6%
13%
11%
CH
Roche Holding AG
SIX:ROG
177.3B CHF
40%
13%
30%
23%
CH
Novartis AG
SIX:NOVN
184.3B CHF
28%
14%
16%
14%
Country US
Market Cap 1.8B USD
ROE
-53%
ROA
-2%
ROCE
10%
ROIC
10%
Country JP
Market Cap 776 550.9T JPY
ROE
-441%
ROA
-47%
ROCE
-108%
ROIC
-64%
Country US
Market Cap 707.9B USD
ROE
49%
ROA
9%
ROCE
30%
ROIC
16%
Country DK
Market Cap 3.9T DKK
ROE
88%
ROA
30%
ROCE
79%
ROIC
36%
Country UK
Market Cap 440.4B GBP
ROE
-4%
ROA
-2%
ROCE
2%
ROIC
2%
Country JP
Market Cap 82T JPY
ROE
1%
ROA
1%
ROCE
2%
ROIC
2%
Country US
Market Cap 360B USD
ROE
56%
ROA
23%
ROCE
18%
ROIC
14%
Country US
Market Cap 321.2B USD
ROE
1%
ROA
0%
ROCE
5%
ROIC
1%
Country UK
Market Cap 176.3B GBP
ROE
16%
ROA
6%
ROCE
13%
ROIC
11%
Country CH
Market Cap 177.3B CHF
ROE
40%
ROA
13%
ROCE
30%
ROIC
23%
Country CH
Market Cap 184.3B CHF
ROE
28%
ROA
14%
ROCE
16%
ROIC
14%

Free Cash Flow

Free cash flow (FCF) is the money a company has left over after paying its operating expenses and capital expenditures. The more free cash flow a company has, the more it can allocate to dividends, paying down debt, and growth opportunities.

If a company has a decreasing free cash flow, that is not necessarily bad if the company is investing in its growth.

See Also

Discover More